How Sapropterin Works in PKU
Sapropterin dihydrochloride (Kuvan) treats phenylketonuria (PKU) by acting as a synthetic form of tetrahydrobiopterin (BH4), the active cofactor for phenylalanine hydroxylase (PAH). In PKU, PAH mutations impair conversion of phenylalanine (Phe) to tyrosine, causing toxic Phe buildup in blood and brain, which leads to intellectual disability, seizures, and behavioral issues if untreated.[1]
Sapropterin binds residual PAH enzyme activity in responsive patients (about 20-50% of those with some PAH function), stabilizing it and restoring up to 30-50% of normal activity. This lowers blood Phe levels, reducing symptoms like cognitive impairment and allowing relaxed dietary restrictions.[2][3]
Why Only Some PKU Patients Respond
Responsiveness depends on PAH mutation type—milder mutations retain BH4-binding sites, enabling sapropterin to enhance folding and catalysis. Patients test positive if Phe drops 30% after an 8-day trial. Non-responders have severe mutations lacking cofactor interaction.[4]
How Long Until Symptom Improvement
Blood Phe reductions occur within hours to days in responders, with sustained effects after 2-4 weeks. Cognitive benefits, like better executive function, appear over months alongside Phe control, but irreversible early damage may persist.[5]
Dosage and Daily Use for Best Results
Adults and children over 4 take 10-20 mg/kg/day, split into 2-3 doses, often with meals to boost absorption. Combine with low-Phe diet; monitor levels weekly initially.[6]
Common Side Effects Patients Experience
Most tolerate it well, but issues include headache (12%), runny nose (9%), sore throat (7%), and rare anaphylaxis. Phe can rise in non-responders, worsening symptoms.[7]
Alternatives if Sapropterin Fails
Non-responders rely on strict Phe-restricted diets, large neutral amino acid supplements, or pegvaliase (Palynziq), an injectable enzyme that breaks down Phe outside cells. Gene therapy trials target root PAH defects.[8]
[1]: National Institutes of Health - PKU Overview
[2]: FDA Label - Kuvan
[3]: BioMarin Pharmaceuticals - Mechanism
[4]: Journal of Inherited Metabolic Disease - BH4 Responsiveness
[5]: Molecular Genetics and Metabolism - Clinical Trials
[6]: Kuvan Prescribing Information
[7]: Drugs.com - Sapropterin Side Effects
[8]: FDA - Palynziq Approval